Core Viewpoint - Clover Biopharmaceuticals-B (02197) experienced a significant stock increase of over 5%, reaching HKD 2.98, following the announcement of positive preliminary data from two ongoing clinical trials [1] Group 1: Clinical Trials - The company is conducting a Phase I clinical trial in Australia to evaluate the respiratory combination vaccine candidates SCB-1022 and SCB-1033 against SCB-1019, targeting elderly individuals who have not previously received any RSV vaccine [1] - In the United States, a Phase I clinical trial is underway to compare SCB-1019 with AREXVY in a head-to-head assessment, focusing on elderly participants who had received at least one dose of AREXVY in the two preceding flu seasons [1] - Based on the positive results from these Phase I trials, Clover Biopharmaceuticals plans to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026 [1]
港股异动 | 三叶草生物-B(02197)高开逾5% 两项临床试验获得积极初步数据